156 related articles for article (PubMed ID: 36428710)
1. Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma.
Kim SJ; Ryu KJ; Park B; Yoon SE; Cho J; Park Y; Kim WS
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428710
[TBL] [Abstract][Full Text] [Related]
2. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
Feng Y; Jing C; Yu X; Cao X; Xu C
Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type.
Li JW; Wei P; Guo Y; Shi D; Yu BH; Su YF; Li XQ; Zhou XY
Am J Cancer Res; 2020; 10(12):4498-4512. PubMed ID: 33415014
[TBL] [Abstract][Full Text] [Related]
4. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
[TBL] [Abstract][Full Text] [Related]
5. Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.
Kim SJ; Lim JQ; Laurensia Y; Cho J; Yoon SE; Lee JY; Ryu KJ; Ko YH; Koh Y; Cho D; Lim ST; Enemark MB; D'Amore F; Bjerre M; Ong CK; Kim WS
Blood; 2020 Dec; 136(24):2754-2763. PubMed ID: 32766875
[TBL] [Abstract][Full Text] [Related]
6. The Role of PD-L1 Expression in Prediction and Stratification of Recurrent or Refractory Extranodal Natural Killer/T-Cell Lymphoma.
Gao LM; Zhang YH; Shi X; Liu Y; Wang J; Zhang WY; Liu WP
Front Oncol; 2022; 12():821918. PubMed ID: 35619907
[TBL] [Abstract][Full Text] [Related]
7. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
[TBL] [Abstract][Full Text] [Related]
8. Optimization of immune checkpoint inhibitor treatment planning for relapsed or refractory extranodal NK/T cell lymphoma.
Yoon SE; Cho H; Berning P; Cho J; Kim HY; Yoon DH; Schmit N; Kim SJ; Kim WS
Ann Hematol; 2024 May; ():. PubMed ID: 38730207
[TBL] [Abstract][Full Text] [Related]
9. Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma.
Ryu KJ; Lee JY; Choi ME; Yoon SE; Cho J; Ko YH; Shim JH; Kim WS; Park C; Kim SJ
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33261029
[TBL] [Abstract][Full Text] [Related]
10. GM-CSF mediates immune evasion via upregulation of PD-L1 expression in extranodal natural killer/T cell lymphoma.
Rong QX; Wang F; Guo ZX; Hu Y; An SN; Luo M; Zhang H; Wu SC; Huang HQ; Fu LW
Mol Cancer; 2021 May; 20(1):80. PubMed ID: 34051805
[TBL] [Abstract][Full Text] [Related]
11. The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis.
Li W; Zheng Q; Luo X; Zhang X; Zheng X; Yang Y
Transl Cancer Res; 2023 Aug; 12(8):2115-2127. PubMed ID: 37701117
[TBL] [Abstract][Full Text] [Related]
12. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
Jo JC; Kim M; Choi Y; Kim HJ; Kim JE; Chae SW; Kim H; Cha HJ
Ann Hematol; 2017 Jan; 96(1):25-31. PubMed ID: 27696202
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab in newly diagnosed EBV-negative extranodal natural killer/T-cell lymphoma: A case report.
Asif S; Begemann M; Bennett J; Fatima R; Masood A; Raza S
Mol Clin Oncol; 2019 Mar; 10(3):397-400. PubMed ID: 30847181
[TBL] [Abstract][Full Text] [Related]
14. Establishment and comprehensive analysis of a new human cell line (NK-NJ) with NK-cell characteristics established from extranodal natural killer cell lymphoma/leukemia.
Liang JH; Wang WT; Du KX; Xing TY; Wang Y; Wang H; Liu L; Guo R; Shao Y; Liang J; Li Y; Shen HR; Wang L; Li JY; Xu W
Hum Cell; 2023 Mar; 36(2):835-846. PubMed ID: 36520345
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
16. Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis.
Wei L; Yang L; Cong J; Ye J; Li X; Yao N; Yang J; Ding J; Wang J
J Cancer Res Clin Oncol; 2021 Mar; 147(3):863-869. PubMed ID: 33025280
[TBL] [Abstract][Full Text] [Related]
17. First-line immunotherapy with anti-PD-1 antibody for extranodal NK/T-cell lymphoma: A retrospective study.
Wang X; Wen L; Liao J; Feng Y; Li Y; Zhou Z; Zhou C; Huang H
Br J Haematol; 2023 Aug; 202(4):812-824. PubMed ID: 37394245
[TBL] [Abstract][Full Text] [Related]
18. Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases.
Du L; Zhang L; Li L; Li X; Yan J; Wang X; Fu X; Sun Z; Zhang X; Li Z; Wu J; Yu H; Chang Y; Zhou Z; Nan F; Wu X; Tian L; Zhang M
Onco Targets Ther; 2020; 13():7189-7197. PubMed ID: 32801749
[TBL] [Abstract][Full Text] [Related]
19. Molecular pathogenic pathways in extranodal NK/T cell lymphoma.
de Mel S; Hue SS; Jeyasekharan AD; Chng WJ; Ng SB
J Hematol Oncol; 2019 Apr; 12(1):33. PubMed ID: 30935402
[TBL] [Abstract][Full Text] [Related]
20. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
